Clinical Trials Directory

Trials / Unknown

UnknownNCT03965598

Study on Predictiors and Mechanism of Conversion to Psychosis in Individuals at Ultra-high Risk Group

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Second Xiangya Hospital of Central South University · Academic / Other
Sex
All
Age
13 Years – 30 Years
Healthy volunteers
Accepted

Summary

Considering the complex pathological mechanism and the poor treatment outcomes of schizophrenia, early detection and intervention gradually become the key work for the foundational and clinical research in schizophrenia. Ultra-high risk for psychosis (UHP) is defined as individuals at the prodromal stage of schizophrenia. Early intervention in individual at UHP can effectively delay or even prevent the development of the illness. Long-term longitudinal studies suggested that there are clinical outcomes in people at UHP. Nearly 1/3 of individuals at UHP may be naturally relieved without any intervention, about 1/3 of individuals at UHP will remain at the prodromal stage of schizophrenia, and only 1/3 individuals at UHP will eventually develop schizophrenia. In this regard, it will cause adverse effects on false positive individuals if they accept clinical intervention. Unfortunately, it is difficult to accurately predict which individuals at UHP will make a transition to frank illness. To solve this issue, we explore the association between baseline brain structural and functional networks, methylation modifications, gene expression, neurocognitive function and the clinical outcomes of UHP individuals, and to identify the potential biological and clinical predictors for the long-term outcomes in the individuals at UHP. In addition, we also detect the changes of brain structure and function, methylation status and gene expression in individuals at UHP during follow-up, and further to investigate the etiology and pathogenesis of schizophrenia.

Conditions

Timeline

Start date
2016-11-01
Primary completion
2021-12-31
Completion
2022-12-31
First posted
2019-05-29
Last updated
2019-05-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03965598. Inclusion in this directory is not an endorsement.